Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

Olivera Pablo; Thiriet Linda; Luc Amandine; Baumann Cedric; Danese Silvio; Peyrin-Biroulet Laurent

首页> 外文期刊>Inflammatory bowel diseases >Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

【24h】

Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

机译：英夫利昔单抗对克罗恩病的治疗持续性：14年的单中心经验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD.

机译：背景：英夫利昔单抗（IFX）和Adaalimumab（Ada）广泛用于治疗克罗恩病（CD）的患者。 CD患者IFX和ADA治疗持久性的公布数据很少。

著录项

来源
《Inflammatory bowel diseases》 |2017年第6期|共10页
作者
Olivera Pablo; Thiriet Linda; Luc Amandine; Baumann Cedric; Danese Silvio; Peyrin-Biroulet Laurent;
展开▼
作者单位

Lorraine Univ Nancy Univ Hosp INSERM U954 Allee Morvan F-54511 Vandoeuvre Les Nancy France;

Lorraine Univ Nancy Univ Hosp INSERM U954 Allee Morvan F-54511 Vandoeuvre Les Nancy France;

Nancy Univ Hosp ESPRI BioBase Unit PARC Clin Res Support Facil Nancy France;

Nancy Univ Hosp ESPRI BioBase Unit PARC Clin Res Support Facil Nancy France;

Humanitas Univ IBD Ctr Milan Italy;

Lorraine Univ Nancy Univ Hosp INSERM U954 Allee Morvan F-54511 Vandoeuvre Les Nancy France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
infliximab; adalimumab; Crohn's disease; persistence; clinical experience;

机译：infliximab;Adalimumab;克罗恩病;持久性;临床经验;

相似文献

外文文献
中文文献
专利

1. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience [J] . Olivera Pablo, Thiriet Linda, Luc Amandine, Inflammatory bowel diseases . 2017,第6期

机译：英夫利昔单抗对克罗恩病的治疗持续性：14年的单中心经验
2. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease [J] . Riis?., MartinsenT.C., WaldumH.L., Scandinavian journal of gastroenterology. . 2012,第6期

机译：英夫利昔单抗和阿达木单抗在克罗恩病患者的单中心队列中的临床经验
3. Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease [J] . Taxonera Carlos, Robledo Pilar, Rodríguez Antonio Revista Espaola de Enfermedades Digestivas . 2017,第10期

机译：阿达木单抗和英夫利昔单抗在克罗恩病治疗中的治疗序列持续治疗
4. Understanding Crohn's disease patients reaction to infliximab from facebook: A medical perspective [C] . M. Roccetti, P. Salomoni, C. Prandi, Proceedings of the 2016 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining . 2016

机译：从facebook了解克罗恩病患者对英夫利昔单抗的反应：医学观点
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohns disease [O] . Cheng-Chun Ji, Shota Takano 2017

机译：阿达木单抗与英夫利昔单抗的临床疗效以及与克罗恩病肛瘘治疗期间复发或加重相关的因素
7. PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY [O] . M. Arhan, H.A. Tezel, M. Toruner, 2018

机译：PGI21 - Ustekinumab与Adalimumab，infliximab和Vedolizumab对土耳其严重活跃克罗恩病患者治疗患者的成本效力分析

Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience

摘要

著录项

相似文献

相关主题

期刊订阅